NDLI: Bioengineered Colorectal Cancer Drugs: Orally Delivered Anti-Inflammatory Agents

Content Provider	Springer Nature Link
Author	Urbanska, Aleksandra Malgorzata Zhang, Xiaoying Prakash, Satya
Copyright Year	2015
Abstract	Intestinal inflammation is one of the major factors that increase colorectal cancer (CRC) incidence worldwide. Inflammation in the gastrointestinal tract is directly linked to tumor development at the early stages of the disease, thus a key issue toward the prevention and the treatment of colonic neoplasia. Thus, the use of anti-inflammatory drugs has emerged first as a strategy to reduce chronic inflammation in case of many inflammatory bowel diseases (IBD), but it has proven its efficacy by reducing the risk of colonic neoplasia. This comprehensive review highlights the role of chronic inflammation, mainly in IBD, in the development of CRC including molecular and immune mechanisms that have tumorigenic effects. Multiple lines of evidence indicate that several bioactive and phytochemical compounds used as anti-inflammatory drugs have also antitumoral attributes. The uses of orally delivered cytokines and small molecules, as well as key dietary supplementation as anti-inflammatory therapeutics are discussed. In addition, comprehensive knowledge about CRC and intestinal inflammation, and the importance of the intestinal mucosal wall as a mucosal immunological barrier that comes into play during interactions with gut microbiota (pathogens and commensal), luminal secretions (bile acids, and bacterial and epithelial metabolites), and ingested chemicals (food components, high fat content, heterocyclic amines, and low intake of dietary fiber) are underscored. The multifunctionality of several anti-inflammatory drugs opens a line for their application in the treatment and prevention not only in IBD but also in CRC. Current bioengineering approaches for oral delivery of anti-inflammatory agents including cytokines, genetically modified bacteria, or small molecule inhibitors of inflammation directly contribute to the early management of CRC. Limitations of the current therapeutics, which stem from the lack of complete understanding of the complex molecular interactions between the intestinal microbiota, colonic epithelial barrier, and host immune system, are also discussed.
Starting Page	757
Ending Page	769
Page Count	13
File Format	PDF
ISSN	10859195
Journal	Cell Biochemistry and Biophysics
Volume Number	72
Issue Number	3
e-ISSN	15590283
Language	English
Publisher	Springer US
Publisher Date	2015-05-23
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Colorectal cancer Inflammation Anti-inflammatory Inflammatory bowel disease Biotherapeutics Phytochemicals Probiotics Small drug molecules Biochemistry Pharmacology/Toxicology Biotechnology Cell Biology Biophysics and Biological Physics
Content Type	Text
Resource Type	Article
Subject	Cell Biology Medicine Biochemistry Biophysics

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Molecular mechanisms of intestinal inflammation leading to colorectal cancer

Non-steroidal Anti-inflammatory Drugs and Hypertension

Angiostatic Properties of Sulindac and Celecoxib in the Experimentally Induced Inflammatory Colorectal Cancer

Compounds against inflammation and oxidative insult as potential agents for neurodegenerative disorders

Susceptibility and REF1 Gene Polymorphism Towards Colorectal Cancer

Diagnosis of Small Bowel Obstruction using Targeted Enterography During Nasointestinal Decompression

Engineered Probiotics for Detection and Treatment of Inflammatory Intestinal Diseases

Clinical Efficacy of Chemotherapy Combined with Verapamil in Metastatic Colorectal Patients

Combination Approach: the Future of the War Against Cancer

Bioengineered Colorectal Cancer Drugs: Orally Delivered Anti-Inflammatory Agents

Similar Documents

Molecular mechanisms of intestinal inflammation leading to colorectal cancer

Non-steroidal Anti-inflammatory Drugs and Hypertension

Angiostatic Properties of Sulindac and Celecoxib in the Experimentally Induced Inflammatory Colorectal Cancer

Compounds against inflammation and oxidative insult as potential agents for neurodegenerative disorders

Susceptibility and REF1 Gene Polymorphism Towards Colorectal Cancer

Diagnosis of Small Bowel Obstruction using Targeted Enterography During Nasointestinal Decompression

Engineered Probiotics for Detection and Treatment of Inflammatory Intestinal Diseases

Clinical Efficacy of Chemotherapy Combined with Verapamil in Metastatic Colorectal Patients

Combination Approach: the Future of the War Against Cancer

Bioengineered Colorectal Cancer Drugs: Orally Delivered Anti-Inflammatory Agents